References
- Allen J, van Loevezijn A, Lakhai J, et al. (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–25
- Björnsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
- Dantzig AH, Shepard RL, Law KL, et al. (1999). Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854–62
- Draper MP, Weir S, Macone A, et al. (2014). Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 58:1279–83
- Gao J, Murase O, Schowen R, et al. (2001). A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 18:171–6
- Geick A, Eichelbaum M, Burk O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–7
- Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242–51
- Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
- Hutzler JM, Cook J, Fleishaker JC. (2011). Drug–drug interactions: designing development programs and appropriate product labeling. In: Bonate PL, Howard DR, eds. Pharmacokinetics in drug development. New York: Springer, 2011, 21–56
- Hoffmann M, DeMaio W, Jordan RA, et al. (2007). Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 35:1543–53
- König J, Müller F, Fromm MF. (2013). Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944–66
- Lai Y, Sampson KE, Stevens JC. (2010). Evaluation of drug transporter interactions in drug discovery and development. Comb Chem High Throughput Screen 13:112–34
- Lin JH. (2007). Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3:81–92
- Lu C, Liao M, Cohen L, Xia CQ. (2010). Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions. Curr Drug Discov Technol 7:199–222
- Macone AB, Caruso BK, Leahy RG, et al. (2014). In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58:1127–35
- Madan A, Graham RA, Carroll KM, et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421–31
- Matsson P, Pedersen JM, Norinder U, et al. (2009). Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816–31
- Meunier V, Bourrie M, Julian B, et al. (2000). Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 30:589–607
- Nelson ML. (2001). The chemistry and cellular biology of tetracyclines. In: Nelson M, Hillen W, Greenwald RA, eds. Tetracyclines in biology, chemistry, and medicine. Basel, Springer AG, 3–63
- Noel GJ, Draper MP, Hait H, et al. (2012). A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56:5650–4
- Russel FGM. (2010). Transporters: Importance in drug absorption, distribution, and removal. Chapter 2. In: Pang K S, Rodrigues AD, Peter RM, eds. Enzyme- and transporter-based drug–drug interactions: progress and future challenges. New York: Springer, 27–49
- Sun H, Ting L, Machineni S, et al. (2012). A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects. Presented at 22nd European Congress of Clinical Microbiology and Infectious Disease, London, UK. Poster P1423. ESCMID eLibrary, ESCMID website
- Yueh MF, Bonzo JA, Tukey RH. (2005). The role of Ah receptor in induction of human UDP-glucuronosyltransferase 1A1. Meth Enzymol 400:75–91